

# List of Figures

1	Proportion of mature products among Top-50 pharma products	6
2	European Pharmaceutical Companies amongst the Global Top-50 Ranking 2008	27
3	ROIC 2005-2007 of publicly listed European originator companies amongst the Global Top-50	29
4	Structure of analysis - IP related generic defense strategies as addressed by the sector inquiry according to their underlying business rationale and the PACE framework	43
5	Pharmaceutical business model transformations according to value chain positioning and targeted innovativeness	72
6	Assessment results of individual IP related generic defense strategies based on the PACE factors	82

